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Abstract 16	  
 17	  
Using a high-power CO2 laser to irradiate powder beds, it was possible to induce 18	  
phase transformation to the amorphous state. Irradiation of a model drug, 19	  
indometacin, resulted in formation of a glass. Varying the settings of the laser (power 20	  
and raster speed) was shown to change the physicochemical properties of the 21	  
glasses produced and all irradiated glasses were found to be more stable than a 22	  
reference glass produced by melt-quenching. Irradiation of a powder blend of 23	  
paracetamol and polyvinylpyrrolidone K30 was found to produce a solid amorphous 24	  
dispersion. The results suggest that laser-irradiation might be a useful method for 25	  
making amorphous pharmaceuticals. 26	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Introduction 34	  
The limiting factor controlling bioavailability of many actives delivered via the oral 35	  
route is solubility. When an active is formulated in the stable crystalline form, 36	  
solubility and dissolution rate are minimised. Poor bioavailability might be overcome 37	  
by formulating the active in a metastable crystal form, although care must be taken 38	  
when using this formulation strategy to ensure there is no conversion to the stable 39	  
polymorph during storage. If the metastable form also does not have acceptable 40	  
solubility then formulation in the amorphous state may be necessary. In cases where 41	  
the drug itself is a good glass former, no excipients are necessary to stabilise the 42	  
amorphous form, but for other drugs incorporation into a polymeric matrix to form a 43	  
solid amorphous dispersion may be necessary.  44	  
 45	  
It follows that methods that may result in phase transformation to an amorphous state 46	  
will always be important, either for evaluation purposes during preformulation or for 47	  
large-scale manufacture. Several methods are well known to produce amorphous 48	  
materials; for instance, spray-drying, freeze-drying, melt-extrusion or melt quenching. 49	  
Spray-drying requires the compound to have appreciable solubility in a suitable 50	  
solvent (which is typically organic, because of the low aqueous solubility) while melt 51	  
quenching requires the compound to be stable upon melting and also requires 52	  
handling of cryogenic liquids, typically liquid nitrogen. Neither freeze-drying or 53	  
quench-cooling are particularly suited to large-scale manufacture, although freeze-54	  
frying is used to prepare thermally-labile compounds, such as proteins, commercially. 55	  
Melt-extrusion is widely use to prepare drug-polymer blends but cannot general be 56	  
used to prepare amorphous samples of pure, low molecular weight compounds. 57	  
 58	  
In principle, any method that can rapidly heat a material above its melt and then 59	  
quench cool has the potential to cause transformation to an amorphous matrix. Since 60	  
a laser is a high-energy power source, we wondered whether irradiating a sample 61	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with a laser, in this case a carbon dioxide (CO2) laser, might be an effective 62	  
approach. CO2 lasers have many applications in the medical (tissue ablation) 63	  
(Landthaler et al, 2004) and chemical (fabrication of microfluidic arrays, Prakash et al, 64	  
2015) fields and we have recently shown that they can cause phase transformations 65	  
in binary powder blends to produce co-crystals (Titapiwatanakun et al, 2016). In that 66	  
work we posited that the laser supplied sufficient energy to the powder blend to raise 67	  
the temperature above the melting point and the compounds mixed and recrystallised 68	  
in a co-crystal lattice. However, the technique appeared to require that the 69	  
compounds sublimed to an appreciable extent for molecular rearrangement to occur, 70	  
suggesting molecular mixing occurred primarily in the vapour phase. The possibility, 71	  
explored in this work, is that for other compounds molecular rearrangement cannot 72	  
occur sufficiently rapidly, either during the heat-cool cycle or because they do not 73	  
vapourise, and so amorphous states may be produced. The hypothesis is tested with 74	  
two model systems; a pure drug substance, indomethacin, and a binary blend of drug 75	  
substance and excipient, paracetamol and polyvinylpyrrolidone K30. Indomethacin 76	  
was selected as it has low aqueous solubility and exists in the solid state in three 77	  
monotropically-related polymorphs (the stable γ form and the metastable α, and δ 78	  
forms) as well as the amorphous state and is known to be a good glass former 79	  
(Andronis and Zografi, 2000; Fukuoka et al, 1986; Otsuka et al, 2001; Crowley and 80	  
Zografi, 2002). In addition, indometacin is well-known to appear yellow in colour 81	  
when amorphous (Tanabe et al, 2012), providing a simple visual reference that 82	  
phase-conversion has occurred, and it is stable in the liquid form. Paracetamol/PVP 83	  
K30 was selected because PVP is known to increase the solubility of paracetamol 84	  
(Afrasiabi Garekani et al, 2003) and because PVP has been shown to inhibit 85	  
crystallization of paracetamol on storage (Miyazaki et al, 2004; Wen et al, 2008). 86	  
 87	  
 88	  
 89	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Materials and methods  90	  
 91	  
Indometacin (γ form, IDM) and paracetamol (monoclinic form I, PARA) were 92	  
purchased from Sigma-Aldrich Ltd. Polyvinylpyrrolidone (PVP K30), was purchased 93	  
from Fluka Analytical (UK). All materials were used as received. 94	  
 95	  
Laser irradiation 96	  
A 40W CO2 laser (Full Spectrum Laser LLC, Las Vegas, US) was used for this study. 97	  
For IDM experiments, an image of a square (3cm x 3cm, 300 dpi) was used as a 98	  
template. IDM powder was spread in a thin layer in sample holders for the respective 99	  
characterisation experiments (DSC and XRPD, see below) so that no additional 100	  
mechanical stress needed to be applied to the sample to move it once irradiated (all 101	  
samples were placed with the 3cm x 3cm area so as to be irradiated by the laser). 102	  
The focal length of the laser was 7.4 cm. The laser allows user selection of power (P) 103	  
and raster speed (S); various combinations were used (P75, P50, P25, S100, S75, 104	  
S50; the numbers reflect the percentage of the maximum speed or power that the 105	  
laser could achieve). Irradiated samples were stored in a desiccator over 106	  
phosphorous pentoxide at ambient temperature until further analysis. 107	  
 108	  
For PARA experiments, an image of a square (5cm x 5cm, 300 dpi) was used as a 109	  
template. Physical mixtures of PARA and PVP K30 at ratios of 30:70, 50:50 and 110	  
70:30 were mixed in a sample bottle. The powder blend (100 mg) was spread on 111	  
aluminium foil as a thin layer and placed in the working field of the laser at a focal 112	  
length of 6.8 cm. A range of laser scanning speeds (100 and 75%) and powers (20, 113	  
30, 40 and 50%) were used. Irradiated samples were transferred from the aluminium 114	  
foil to a small vial and stored in a desiccator over P2O5 until use. 115	  
 116	  
 117	  
	   6	  
Melt quenching 118	  
Crystalline IDM was melted on aluminium foil at 165 oC for 3 min and then quench-119	  
cooled by dropping into liquid nitrogen. The resulting amorphous solid was warmed 120	  
to room temperature before being stored in a desiccator over P2O5.  121	  
 122	  
X-Ray Powder Diffraction (XRPD) 123	  
Data were collected on a Miniflex 600 diffractometer (Rigaku, Tokyo, Japan) with Cu 124	  
Kα radiation at 40 kV and 15 mA. Samples were contained within a zero background 125	  
holder. Scanning was performed from 5°-35° 2θ at 0.01° 2θ step size and speed 5° 126	  
2θ/min.  127	  
 128	  
Differential Scanning Calorimetry (DSC) 129	  
DSC measurements were made with a Q2000 (TA Instruments, LLC, USA). Samples 130	  
(3-5 mg) were encapsulated in Tzero aluminium pans and lids. Samples were heated 131	  
from -50 to 175 oC at a heating rate of 10 °C/min. Modulated Differential Scanning 132	  
Calorimetry (MDSC) experiments were performed using the modulated mode with an 133	  
underlying heating rate of 3 °C/min, a modulation amplitude of ±1 °C and a 134	  
modulation period of 60 s. The instrument was calibrated using a standard reference 135	  
material (indium, Tm = 156.6, ΔH = 28.71 J/g) in accordance with the manufacturer’s 136	  
instructions. Data were analysed with Universal Analysis 2000 (TA Instruments, LLC, 137	  
USA). Experiments were performed in triplicate. Crystallization and melting values 138	  
are reported as extrapolated onset (Tonset) while glass transition temperatures (Tg), 139	  
are calculated as the mid-point (Tm). 140	  
 141	  
Fourier-Transform Infrared (FT-IR) 142	  
Data were obtained with a 100 FT-IR spectrophotometer (Perkin Elmer). The 143	  
spectrum of an empty cell was used as the background. The scan was performed in 144	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the range of 4000 to 650 cm-1 for each sample at ambient conditions. Spectrum 145	  
Express software (version 2008) was used to process the data. 146	  
 147	  
Scanning Electron Microscopy (SEM) 148	  
Samples were mounted on an aluminium stage using adhesive tape and sputter-149	  
coated with gold (Quorum model Q150, Quorum Technology, UK) at 40 mA. Images 150	  
were collected using an SEM (SEM, Quanta 200 FEG, FEI, Netherlands).   151	  
 152	  
Stability testing 153	  
IDM samples were evaluated for stability under three conditions: at room temperature 154	  
over P2O5, at 40 oC/0% RH and 40 oC/75% RH. The physical form of the samples 155	  
was monitored at various time intervals with XRPD as described above.  156	  
 157	  
Results and discussion  158	  
Irradiation of indometacin 159	  
Immediately following laser irradiation, a change in colour of the IDM powder from 160	  
white to yellow was observed and the powder bed transformed to a contiguous glass 161	  
(Figure 1). The yellow colour immediately indicated formation of an amorphous state 162	  
(Bahl and Bogner, 2008; Fukuoka et al, 1996; Heinz et al, 2007; Wu et al, 2007) and 163	  
occurs not because of chemical degradation but because the colour of solid organic 164	  
materials depends on electron delocalisation and molecular interactions (Tanabe et 165	  
al, 2012). Although it was not possible to measure the increase in local temperature 166	  
caused by irradiation, because the laser was focussed on any particular point for a 167	  
very short (ms) time, the fact that phase-conversion occurred indicated that the 168	  
temperature rise must have been greater than the melting point of indometacin (159 169	  
oC). It was seen that the shade of the irradiated samples differed with the level of 170	  
irradiation, with higher power producing darker, more translucent samples, Figure 2. 171	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Reducing the focal distance to 6.8 cm caused blackening of the glass, indicative of 172	  
thermal degradation. 173	  
 174	  
The solid state forms of the IDM samples were determined with XRPD. The 175	  
crystalline raw material (RM) showed a number of intensity maxima, characteristic of 176	  
the γ-form and consistent with literature (Aceves-Hernandez et al, 2009). The melt-177	  
quenched (LN2) and all irradiated samples showed broad haloes, indicating their 178	  
amorphous nature, Figure 3. 179	  
 180	  
IDM RM showed a sharp melting endotherm at 159 oC by DSC (data not shown), 181	  
consistent with the γ-form. DSC data for the irradiated and melt-quenched samples 182	  
are shown in Figure 4.  All samples exhibited a glass transition at ca. (at 38 ± 1 °C), 183	  
followed by crystallisation (the broad exotherms) and then melting (the sharp 184	  
endotherms). The glass transition values (given in Table 1) varied slightly with the 185	  
laser settings. Fukuoka et al (1996) showed that the Tg of indomethacin was 186	  
dependent on the cooling rate during formation of the glass, so it seems likely that 187	  
the same effect occurs here, with different laser settings causing different heating 188	  
and cooling rates. Similarly, the temperature at which each sample recrystallizes is 189	  
also seen to vary with the laser settings. This presumably also indicates that on a 190	  
molecular level, the degree of short-range ordering within the amorphous matrix 191	  
differs between the samples. This means the barrier to recrystallization is higher for 192	  
some samples and so the temperature at which they recrystallize increases. All 193	  
samples crystallise to the stable γ-form, evidenced by sharp melting around 159 oC. 194	  
 195	  
FTIR spectra of the IDM samples are shown in Figure 5. The sharp bands at 1713 196	  
and 1690 cm-1 can be assigned to the asymmetric acid C=O and the benzoyl C=O 197	  
respectively in the crystalline γ-form (Patterson et al, 2005; Strachan et al, 2007). 198	  
These bands are shifted to 1708  and 1680 cm-1 respectively for the amorphous 199	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samples, and an additional band at 1735 cm-1 (assigned to non-hydrogen bonded 200	  
C=O) is seen. The absorption bands at 1314 and 1219 cm-1, within the fingerprint 201	  
region, were found to be broader in the amorphous samples. This suggested that 202	  
there was a difference between the crystalline and amorphous states in terms of 203	  
vibrational transitions, which indicates weaker intermolecular bonding of molecules in 204	  
the amorphous samples.  205	  
 206	  
Samples were amorphous immediately following irradiation and showed no evidence 207	  
of recrystallising when stored at room temperature for 6 days (Figure 6). Upon 208	  
storage at elevated temperature (40 oC) but dry conditions the quench-cooled sample 209	  
showed the appearance of diffraction peaks after 2 days, which increased in intensity 210	  
after 6 days, while the S100P50 irradiated sample remained amorphous. Upon 211	  
storage at elevated temperature (40 oC) and humidity (75% RH) both the quench-212	  
cooled sample and the S100P50 irradiated sample showed the appearance of 213	  
diffraction peaks after 2 days, which increased in intensity after 6 days. The S100P75 214	  
and S100P25 samples behaved similarly to the S100P50 sample (data not shown). 215	  
These observations correlate with the DSC data, in that the irradiated samples have 216	  
a higher barrier to recrystallization to overcome, and so are more stable on storage 217	  
with respect to temperature, although the presence of water acts as a plasticizer, 218	  
crystallising all samples.  219	  
 220	  
Irradiation of PARA/PVP K30 221	  
The SEM images in Figure 7 show PARA appeared as broken needle shaped 222	  
crystals, whereas PVP K30 particles were irregularly rounded with cracks and 223	  
fissures. Irradiated blends clearly passed through a molten phase and changed in 224	  
visual appearance. At the lowest laser power of S100P20, separate phases of PARA 225	  
and PVP K30 were seen, suggesting incomplete melting of the starting materials 226	  
during irradiation. As the irradiation power increased to S75P40, it was evident that 227	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the original morphology of the powder had disappeared and the sample appeared 228	  
more as a contiguous solid phase.  229	  
 230	  
It was observed visually that samples irradiated at lower powers (20 and 30%) had a 231	  
white colour, like the physical blends, while samples irradiated at higher powers were 232	  
a very light yellow in colour, but showed no evidence of charring. Since PARA alone 233	  
when irradiated remained white it is likely that the light yellow colour came from the 234	  
PVP K30. It is of note that irradiation at P50 caused a very sticky thin wax to form on 235	  
the aluminium foil substrate, which was relatively difficult to handle. On balance, 236	  
irradiation at S100P30 was optimal. 237	  
 238	  
The XRPD pattern of PARA shows numerous intensity maxima, consistent with 239	  
PARA form 1 (15.2, 17.8, 20.0, 23.1 and 24.0°), while PVP K30 exhibits a halo 240	  
indicating it is amorphous, Figures 8. XRPD diffraction patterns for PARA/PVP K30 241	  
blends are shown in Figures 8-10. It is apparent that irrespective of the drug/polymer 242	  
ratio, irradiating at the lowest power (S75P20) produced a material with evidence of 243	  
crystallinity, presumably the PARA. Using a co-solvent preparation method, de 244	  
Villiers et al (1998) reported similar data with crystalline PARA dispersed in PVP K30. 245	  
When the irradiation power increased the peaks were seen to disappear, indicating 246	  
complete formation of a solid amorphous dispersion, although the actual power 247	  
needed was dependent upon the proportion of PARA, higher drug loadings requiring 248	  
more power. The shape and position of the amorphous halos were different, probably 249	  
because of differences in orientation and conformation between PARA and K30 250	  
molecules via hydrogen bonding interactions, which may affect the amorphous 251	  
packing density of polymer chains (Murthy et al, 1993). In addition Bikiaris et al 252	  
(2005),  reported that an increased amount of amorphous drug may contribute to a 253	  
change in the XRPD shape.  254	  
 255	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When analysed with DSC, those samples shown to be amorphous dispersions by 256	  
XRPD showed only a single glass transition (values in Table 2). Several empirical 257	  
equations have been derived to predict the Tg of homogeneous binary systems (for 258	  
instance, the Gordon-Tayor and Fox equations). The Fox equation (Fox, 1956) 259	  
predicts an intermediate Tg based on the weight fractions of the components; 260	  
 261	   !!! = !!!!,! +    !!!!,! 262	  
 263	  
Where W is the weight fraction of each component and the numerical subscripts refer 264	  
to the component materials. The glass transition temperature of pure PARA is ca. 265	  
25°C (Qi et al, 2008) while that of K30, measured here by DSC (data not shown), is 266	  
160 oC, so assuming ideal mixing, the Fox equation predicts glass transition 267	  
temperatures of 61.1, 43.3 and 33.5 for PARA:K30 (in ratios of 30:70, 50:50 and 268	  
70:30 respectively). These values correlate well with the measured temperatures of 269	  
42-63 °C indicating miscibility of the drug and polymer.  270	  
 271	  
 272	  
Conclusion 273	  
It has been demonstrated that irradiating crystalline powders with a high-power laser 274	  
causes phase transformation to the amorphous phase. Varying the laser settings of 275	  
power and raster speed didn’t influence whether phase transformation occurred, but 276	  
did appear to affect the physicochemical properties of the resulting materials. Pure 277	  
indometacin was found to transform to a glass, which was more stable upon storage 278	  
than a melt-quenched reference material. Mixtures of PARA and PVP K30 were 279	  
found to transform to a solid amorphous dispersion at higher irradiation powers. 280	  
While we do not envisage laser irradiation as being a method suitable for large-scale 281	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manufacture, it does seem to offer a new route to the amorphous form that might be 282	  
useful during preformulation characterisation. 283	  
  284	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 353	  
Sample Tg (oC) Trecryst (oC) Tm (oC) 
LN2 39.2 84.9 158.7 
S100P25 36.9 88.6 159.8 
S100P50 38.1 101.7 158.7 
S100P75 39.1 107.0 157.9 
 354	  
Table 1: Phase transition temperatures for melt-quenched and laser-irradiated 355	  
IDM samples from DSC data 356	  
 357	  
  358	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Sample Irradiation setting Tg (oC) 
30:70 PARA:PVP K30 S100P50 47.0 
30:70 PARA:PVP K30 S40P75 51.2 
30:70 PARA:PVP K30 S50P75 63.6 
50:50 PARA:PVP K30 S50P75 41.9 
 359	  
Table 2. Glass transition temperatures determined by MDSC for various solid 360	  
amorphous dispersions 361	  
  362	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 363	  
 364	  
Figure 1. IDM sample during irradiation with the CO2 laser, showing crystalline 365	  
powder around the edge and a glass in the 3 x 3 cm square exposed to the 366	  
laser beam  367	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 368	  
 369	  
 370	  
 
 
 
 
 371	  
Figure 2: Images of laser-irradiated IDM samples at various speed (S) and 372	  
power (P) settings. From top to bottom, S100P25, S75P25, S50P25 all at a focal 373	  
length of 7.4 cm and S100P25 at a focal length of 6.8 cm. 374	  
 375	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 393	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 395	  
 396	  
 397	  
Figure 3. XRPD diffraction patterns for IND raw material (RM), melt quenched 398	  
(LN2) and laser-irradiated at various settings of speed (S) and power (P). 399	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 405	  
 406	  
 407	  
 408	  
Figure 4. DSC traces for the melt-quenched (LN2) and laser-irradiated 409	  
(S100P25, S100P50 and S100P75) IDM samples. 410	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Figure 5. FTIR spectra for the raw material (RM), melt-quenched (LN2) and 416	  
laser-irradiated (S100P25, S100P50 and S100P75) IDM samples. 417	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Figure 6. XRPD diffraction patterns for quench-cooled (LN2) and laser-422	  
irradiated (S100P50) IDM samples as a function of time and storage conditions. 423	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 426	  
Figure 7: SEM images of PARA:PVP K30 physical mixture (top) and 30:70 and 427	  
50:50 mixtures following irradiation at S75P40 (middle) and S100P20 (bottom). 428	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 430	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Figure 8. XRPD diffraction patterns for PARA raw material, PVP K30 raw 434	  
material and 30:70 PARA:PVP K30 mixtures irradiated with different laser 435	  
powers 436	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Figure 9. XRPD diffraction patterns for PARA raw material, PVP K30 raw 439	  
material and 50:50 PARA:PVP K30 mixtures irradiated with different laser 440	  
powers 441	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   27	  
5 10 15 20 25 30 35
paracetamol
PVP K30
70:30 PHY
PHY S75P20
PHY S75P30
PHY S75P40
PHY S75P50
2θ (degrees)
In
te
ns
ity
 444	  
Figure 10. XRPD diffraction patterns for PARA raw material, PVP K30 raw 445	  
material and 70:30 PARA:PVP K30 mixtures irradiated with different laser 446	  
powers 447	  
 448	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